UNSPSC 51162339: Atropine/chlorpheniramine/ephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

UNSPSC 51162339 Atropine/chlorpheniramine/ephedrine is a Commodity code that captures state and local procurement of emergency medical and pharmaceutical products, specifically naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals for community health and public safety initiatives. Recent solicitations show state and local governments using this code to source naloxone kits and complementary harm-reduction products for emergency response and community health programs, as well as broader generic pharmaceutical and over-the-counter product portfolios for health facilities and cooperative purchasing networks. Issuing bodies include county health departments and state-administered cooperative purchasing alliances; Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, have posted activity in the past twelve months.

Geographic activity concentrates in Florida and Minnesota, with MMCAP's scope extending to participating state and local government facilities in Oregon. Representative recent opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, and response due July 26, 2026; and MMCAP's RFP S1070000015802, posted January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products across participating jurisdictions, with responses due March 26, 2026 and contract effectiveness set for July 1, 2026. Both solicitations required vendors to meet cGMP compliance, maintain comprehensive liability insurance, and submit detailed product information; MMCAP explicitly required pricing to be submitted through authorized wholesalers and compliance with the Drug Supply Chain Security Act.